Chronic Kidney Disease and Charcot Neuro-Osteoarthropathy of Foot in Diabetes.

Jayaditya Ghosh, Durairaj Arjunan, Raveena Singh, Sanjay Kumar Bhadada, Ashu Rastogi
{"title":"Chronic Kidney Disease and Charcot Neuro-Osteoarthropathy of Foot in Diabetes.","authors":"Jayaditya Ghosh, Durairaj Arjunan, Raveena Singh, Sanjay Kumar Bhadada, Ashu Rastogi","doi":"10.1177/15347346241265751","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Charcot neuro-osteoarthropathy (CNO) occurs late in diabetes and may cause fracture, deformity, and higher mortality. Diabetic kidney disease (DKD) affects bone metabolism and contributes to mortality. However, there is no data on prevalence of CNO and its outcomes with coexisting DKD (or chronic kidney disease [CKD]).</p><p><strong>Methods: </strong>To ascertain the prevalence of CKD (pick CKD or DKD) among patients with CNO and delineate the remission of active CNO and subsequent lower extremity amputation and all-cause mortality during prospective follow-up. Consecutive patients with diabetic CNO (active or inactive) were enrolled and subsequently divided into those with and without CKD (pick CKD or DKD) (Group A and Group B, respectively). A preestablished timeframe of 36 weeks was utilized to evaluate the remission proportion of active CNO.</p><p><strong>Results: </strong>A total of 493 CNO patients were observed and 449 subjects (150 patients had active CNO) were further evaluated. The overall prevalence of diabetic nephropathy (DKD or CKD?) CNO was 43.7%. The proportion of patients achieving remission was significantly lower in Group A compared to Group B (OR 0.468, CI [0.239-0.934], <i>P</i> = .025), however, the median time for achieving remission was similar between the 2 groups (14 weeks vs 16 weeks, <i>P</i> = .885). Overall, all-cause mortality was notably higher Group A compared to Group B (OR 2.23, 95% CI [1.474-3.368]) over a median follow-up of 4 years. No significant differences were observed in rates of diabetic foot ulcers (58.2% vs 54.9%; <i>P</i> = .584) and amputations (17.4% vs 15.12%; <i>P</i> = .889) between Group A and Group B.</p><p><strong>Conclusion: </strong>Patients of CNO with coexisting CKD have poor prognosis both in terms of likelihood of active CNO remission and higher mortality.</p>","PeriodicalId":94229,"journal":{"name":"The international journal of lower extremity wounds","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The international journal of lower extremity wounds","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/15347346241265751","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Charcot neuro-osteoarthropathy (CNO) occurs late in diabetes and may cause fracture, deformity, and higher mortality. Diabetic kidney disease (DKD) affects bone metabolism and contributes to mortality. However, there is no data on prevalence of CNO and its outcomes with coexisting DKD (or chronic kidney disease [CKD]).

Methods: To ascertain the prevalence of CKD (pick CKD or DKD) among patients with CNO and delineate the remission of active CNO and subsequent lower extremity amputation and all-cause mortality during prospective follow-up. Consecutive patients with diabetic CNO (active or inactive) were enrolled and subsequently divided into those with and without CKD (pick CKD or DKD) (Group A and Group B, respectively). A preestablished timeframe of 36 weeks was utilized to evaluate the remission proportion of active CNO.

Results: A total of 493 CNO patients were observed and 449 subjects (150 patients had active CNO) were further evaluated. The overall prevalence of diabetic nephropathy (DKD or CKD?) CNO was 43.7%. The proportion of patients achieving remission was significantly lower in Group A compared to Group B (OR 0.468, CI [0.239-0.934], P = .025), however, the median time for achieving remission was similar between the 2 groups (14 weeks vs 16 weeks, P = .885). Overall, all-cause mortality was notably higher Group A compared to Group B (OR 2.23, 95% CI [1.474-3.368]) over a median follow-up of 4 years. No significant differences were observed in rates of diabetic foot ulcers (58.2% vs 54.9%; P = .584) and amputations (17.4% vs 15.12%; P = .889) between Group A and Group B.

Conclusion: Patients of CNO with coexisting CKD have poor prognosis both in terms of likelihood of active CNO remission and higher mortality.

慢性肾病和糖尿病足的夏科神经骨关节病。
导言:夏科神经骨关节病(CNO)发生于糖尿病晚期,可能导致骨折、畸形和更高的死亡率。糖尿病肾病(DKD)会影响骨代谢并增加死亡率。然而,目前还没有关于糖尿病肾病(或慢性肾病 [CKD])的 CNO 患病率及其结果的数据:方法:确定 CNO 患者中 CKD(摘取 CKD 或 DKD)的患病率,并在前瞻性随访中明确活动性 CNO 的缓解情况以及随后的下肢截肢和全因死亡率。糖尿病 CNO(活动性或非活动性)患者连续入组,随后分为有 CKD 和无 CKD(选择 CKD 或 DKD)患者(分别为 A 组和 B 组)。评估活动性 CNO 的缓解比例时使用了预先设定的 36 周时限:结果:共观察了 493 名 CNO 患者,并对 449 名受试者(150 名患者为活动性 CNO)进行了进一步评估。糖尿病肾病(DKD 或 CKD?)CNO 的总发病率为 43.7%。与 B 组相比,A 组获得缓解的患者比例明显较低(OR 0.468,CI [0.239-0.934],P = .025),但两组获得缓解的中位时间相似(14 周 vs 16 周,P = .885)。总体而言,在中位随访 4 年期间,A 组的全因死亡率明显高于 B 组(OR 2.23,95% CI [1.474-3.368])。在糖尿病足溃疡率(58.2% vs 54.9%;P = .584)和截肢率(17.4% vs 15.12%;P = .889)方面,A 组和 B 组之间没有观察到明显差异:结论:合并有慢性肾脏病的 CNO 患者预后较差,无论是在 CNO 积极缓解的可能性方面还是在死亡率方面都较高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信